2.8K views · 75 reactions | CAR T cell therapy is widely considered to be a revolutionary treatment for blood cancers, with promise to tackle solid tumors in the future. But in the early days of its development, researchers struggled to receive funding for clinical trials. Director of Cell Therapy and Transplant David Porter, MD, looks back at those initial obstacles and the lifesaving success that eventually followed. | Penn Medicine - Abramson Cancer Center | Facebook

Efficient culturing of human mesenchymal stromal cells for cell therapy research

Center for Embryonic Cell and Gene Therapy